In preclinical studies, bemcentinib (BGB324), a selective Axl inhibitor, has demonstrated the ability to block immunosuppressive macrophage polarization and restore antigen presentation in models of non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), melanoma, and pancreatic ductal adenocarcinoma (PDAC). Here, AXL is linked to triple-negative breast carcinoma.